Brief: Vallon Pharmaceuticals Announces Achievement Of Last Patient Last Visit In Pivotal Seal Study For Lead Program, Adair
23/12/2021 13:17
Dec 23 (Reuters) - Vallon Pharmaceuticals Inc VLON.O :
* VALLON PHARMACEUTICALS ANNOUNCES ACHIEVEMENT OF LAST
PATIENT
LAST VISIT IN PIVOTAL SEAL STUDY FOR LEAD PROGRAM, ADAIR
* VALLON PHARMACEUTICALS INC - TOPLINE RESULTS FROM PIVOTAL
SEAL
STUDY EXPECTED IN Q1 2022
Source text for Eikon: ID:nGNX1gvXMq
Further company coverage: VLON.O
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027